HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Longtime Shareholders in Regeneron Pharmaceuticals (REGN) to Contact its Attorneys: Firm Investigating Possible Breach of Fiduciary Duties

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Longtime Shareholders in Regeneron Pharmaceuticals (REGN) to Contact its Attorneys: Firm Investigating Possible Breach of Fiduciary Duties

PR Newswire

SAN FRANCISCO, July 2, 2020 /PRNewswire/ -- Hagens Berman urges longtime shareholders in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to submit their losses now.  The firm is investigating whether Regeneron's directors breached their fiduciary duties. 

Relevant Holding Period: At least 2013 – the present
Visitwww.hbsslaw.com/investor-fraud/REGN 
Contact an Attorney Now[email protected] 
                                             844-916-0895

Regeneron Pharmaceuticals (REGN) Shareholder Investigation:

The investigation focuses on whether Regeneron's directors breached their oversight duties by disregarding senior management's alleged violation of Medicare's anti-kickback laws.

Regeneron's Eylea drug treats macular degeneration, the leading cause of blindness in seniors.  The pricey drug, which costs over $10,000 per year, has become Regeneron's flagship product.  The federal government is among Eylea's greatest sources of revenue through Medicare.

On June 24, 2020, the DOJ sued Regeneron, accusing it of using a charity that helps cover Medicare patients' drug costs to facilitate illegal kickbacks for using Eylea.  Following Eylea's launch in 2011, Regeneron allegedly began funneling millions of dollars through a patient assistance foundation to ensure Medicare patients would not have to make co-pays.  From 2013 to 2014, when the scheme operated, Medicare paid $1.9 billion for Eylea.

The DOJ contends that Regeneron's conduct violated Medicare's anti-kickback statute, which prohibits "indirect" kickbacks to subsidize a Medicare drug's price. The DOJ alleges that senior management knew the conduct was illegal. In 2013, Regeneron's auditors twice inquired about the information Regeneron received from the foundation about Eylea.  But both times, senior management lied, denying that the company received Eylea-specific data. In truth, Regeneron obtained regular Eylea-specific reports from the foundation and then used that data to correlate the company's payments to the foundation.  Consequently, physicians prescribing Eylea neglected to consider its substantial cost, because they knew that the foundation would cover their patients' Medicare co-pays.

"We're focused on whether Regeneron's Board failed to monitor senior management, and if Regeneron has suffered resulting damages," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of Regeneron and suffered losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 844-916-0895

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hagens-berman-national-trial-attorneys-encourages-longtime-shareholders-in-regeneron-pharmaceuticals-regn-to-contact-its-attorneys-firm-investigating-possible-breach-of-fiduciary-duties-301087945.html

SOURCE Hagens Berman Sobol Shapiro LLP

Copyright CNW Group 2020

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).